{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:12:46Z","timestamp":1790442766207,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"UNC University Cancer Research Fund"},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute of the National Institutes of Health"},{"name":"NCI Center Core Support","award":["CA16086"],"award-info":[{"award-number":["CA16086"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jpba.2015.11.035","type":"journal-article","created":{"date-parts":[[2015,11,28]],"date-time":"2015-11-28T17:30:09Z","timestamp":1448731809000},"page":"122-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues"],"prefix":"10.1016","volume":"119","author":[{"given":"Andrew T.","family":"Lucas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"O\u2019Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene M.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor F.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2015.11.035_bib0005","unstructured":"Doxorubicin, [package insert], Bedford Laboratories, Bedford, OH, 2010."},{"key":"10.1016\/j.jpba.2015.11.035_bib0010","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the good, the bad and the ugly effect","volume":"25","author":"Carvalho","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jpba.2015.11.035_bib0015","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jpba.2015.11.035_bib0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2001.26431","article-title":"Anthracycline-induced cardiomyopathy","volume":"28","author":"Keefe","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jpba.2015.11.035_bib0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0026-895X(25)13158-1","article-title":"Daunomycin-DNA dissociation kinetics","volume":"33","author":"Phillips","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jpba.2015.11.035_bib0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/1568011033482378","article-title":"Apoptosis induced by topoisomerase inhibitors","volume":"3","author":"Sordet","year":"2003","journal-title":"Curr. Med. Chem. Anti Cancer Agents"},{"key":"10.1016\/j.jpba.2015.11.035_bib0035","first-page":"8194","article-title":"Molecular basis for the synergistic interaction of Adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9)","volume":"61","author":"Cutts","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2015.11.035_bib0040","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/mol.104.002634","article-title":"Doxorubicin inhibits DNMT1 resulting in conditional apoptosis","volume":"66","author":"Yokochi","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jpba.2015.11.035_bib0045","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jpba.2015.11.035_bib0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","article-title":"A comparison of liposomal formulations of doxorubicin with drug administered in free form","volume":"24","author":"Waterhouse","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.jpba.2015.11.035_bib0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1","article-title":"Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes","volume":"86","author":"Symon","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.jpba.2015.11.035_bib0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15216540500079093","article-title":"The power and potential of doxorubicin-DNA adducts","volume":"57","author":"Cutts","year":"2005","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jpba.2015.11.035_bib0065","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1021\/bi00475a032","article-title":"Induction of stable transcriptional blockage sites by Adriamycin: GpC specificity of apparent Adriamycin-DNA adducts and dependence on iron(III) ions","volume":"29","author":"Cullinane","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.jpba.2015.11.035_bib0070","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1021\/jm960835d","article-title":"Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs Adriamycin and daunomycin","volume":"40","author":"Taatjes","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2015.11.035_bib0075","doi-asserted-by":"crossref","first-page":"11561","DOI":"10.1073\/pnas.95.20.11561","article-title":"Characterization of covalent Adriamycin-DNA adducts","volume":"95","author":"Zeman","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpba.2015.11.035_bib0080","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1021\/bi00230a002","article-title":"Formaldehyde crosslinks daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies","volume":"30","author":"Wang","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.jpba.2015.11.035_bib0085","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/jm960519z","article-title":"Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin","volume":"39","author":"Taatjes","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2015.11.035_bib0090","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.1021\/bi990553q","article-title":"Quantification of formaldehyde-mediated covalent adducts of Adriamycin with DNA","volume":"38","author":"Luce","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.jpba.2015.11.035_bib0095","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1093\/nar\/23.13.2450","article-title":"Use of oligonucleotides to define the site of interstrand crosslinks induced by Adriamycin","volume":"23","author":"Cutts","year":"1995","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpba.2015.11.035_bib0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/nar\/23.1.42","article-title":"Stability of driamycin-induced DNA adducts and interstrand crosslinks","volume":"23","author":"van Rosmalen","year":"1995","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpba.2015.11.035_bib0105","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1093\/nar\/22.12.2296","article-title":"Formation of driamycin-DNA adducts in vitro","volume":"22","author":"Cullinane","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpba.2015.11.035_bib0110","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1093\/nar\/gkn439","article-title":"Detection of adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant adriamycin concentrations","volume":"36","author":"Coldwell","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpba.2015.11.035_bib0115","first-page":"661","article-title":"Sequence specificity of Adriamycin-DNA adducts in human tumor cells","volume":"2","author":"Cutts","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jpba.2015.11.035_bib0120","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1158\/0008-5472.CAN-05-3410","article-title":"Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death","volume":"66","author":"Swift","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2015.11.035_bib0125","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1021\/ac001498q","article-title":"Formaldehyde in human cancer cells: detection by preconcentration chemical ionization mass spectrometry","volume":"73","author":"Kato","year":"2001","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2015.11.035_bib0130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1021\/tx000008m","article-title":"Mass spectrometric measurement of formaldehyde generated in breast cancer cells upon treatment with anthracycline antitumor drugs","volume":"13","author":"Kato","year":"2000","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jpba.2015.11.035_bib0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.talanta.2008.10.043","article-title":"Selective determination of doxorubicin and doxorubicinol in rat plasma by HPLC with photosensitization reaction followed by chemiluminescence detection","volume":"78","author":"Ahmed","year":"2008","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2015.11.035_bib0140","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s002800050999","article-title":"Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients","volume":"44","author":"Andersen","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2015.11.035_bib0145","first-page":"3645","article-title":"Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?","volume":"5","author":"Hong","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2015.11.035_bib0150","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515302521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515302521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T15:55:56Z","timestamp":1748706956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708515302521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":30,"alternative-id":["S0731708515302521"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2015.11.035","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2015.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}